DARMSTADT, Germany--(BUSINESS WIRE)--Merck’s Consumer Health division has made substantial progress in driving the turnaround of the business, raising profitability levels to those of other global over-the-counter (OTC) industry leaders. Based on its third-quarter earnings (published on November 14, 2013), the profit margin, or EBITDA pre one-time items as a percentage of sales, was at 18.4 percent, significantly higher than the 14.2 percent in September 2011. The improvement was mainly due to a strong focus on strategic brands such as Bion®, Nasivin®, Femibion® and Kytta®, and better allocation of resources in key markets. For the first nine months, EBITDA pre one-time items grew by 22% to € 58 million, compared with the year-earlier period, resulting in a raised profit forecast to € 73-77 million for 2013.
Help employers find you! Check out all the jobs and post your resume.
